ProfileGDS5678 / 1445910_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 34% 34% 33% 33% 33% 33% 33% 32% 34% 33% 33% 33% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8075834
GSM967853U87-EV human glioblastoma xenograft - Control 22.7631234
GSM967854U87-EV human glioblastoma xenograft - Control 32.7664834
GSM967855U87-EV human glioblastoma xenograft - Control 42.6968633
GSM967856U87-EV human glioblastoma xenograft - Control 52.6972733
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8385833
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8003133
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7379733
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7150532
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.749534
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7490433
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.721333
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7556433
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7546634